Last 7 days
-6.1%
Last 30 days
94.0%
Last 90 days
306.9%
Trailing 12 Months
-77.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 125.3B | 26.3B | -2.75% | 3.76% | 19.12 | 4.76 | 1.32% | 11.18% |
GILD | 99.6B | 27.3B | -8.96% | 41.01% | 21.68 | 3.65 | -0.09% | -26.23% |
MRNA | 58.4B | 19.3B | -12.76% | 1.00% | 6.99 | 3.03 | 4.29% | -31.47% |
BIIB | 38.3B | 10.2B | -9.67% | 32.94% | 12.57 | 3.76 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.1B | 1.5B | -9.09% | 3.35% | 58.87 | 6.11 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -21.10% | -19.55% | -9.78 | 29.38 | 122.90% | -12.19% |
BEAM | 2.5B | 60.9M | -18.47% | -36.46% | -8.76 | 41.55 | 17.51% | 22.00% |
BBIO | 2.1B | 107.9M | 22.95% | 67.45% | -4.29 | 19.27 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -14.86% | -46.41% | -4.63 | 11.04 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -22.18% | 24.65% | -7.11 | 158.97 | 131.81% | -45.39% |
FATE | 541.9M | 96.3M | -12.99% | -82.24% | -1.92 | 5.63 | 72.44% | -32.79% |
NVAX | 513.7M | 2.0B | -39.67% | -92.01% | -0.78 | 0.26 | 72.89% | 62.27% |
SGMO | 355.3M | 111.3M | -30.55% | -58.78% | -1.85 | 3.19 | 0.54% | -7.86% |
VXRT | 101.4M | 159.0K | -16.47% | -82.96% | -0.97 | 637.62 | -86.46% | -64.56% |
IBIO | 25.1M | - | 94.03% | -77.12% | -0.31 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | -100.0% | 2,383 | 2,686 | 1,508 | 2,045 | |
Gross Profit | -10.6% | 2,167 | 2,425 | 802 | 1,241 | - |
Operating Expenses | -5.1% | 49,228 | 51,857 | 36,360 | 29,758 | - |
S&GA Expenses | -6.2% | 32,014 | 34,128 | 24,719 | 21,506 | - |
R&D Expenses | -2.9% | 17,214 | 17,729 | 11,641 | 8,252 | - |
Interest Expenses | -50.9% | 693 | 1,412 | 1,473 | 1,835 | - |
Net Income | -61.3% | -81,127 | -50,303 | -33,134 | -28,405 | - |
Net Income Margin | -549.8% | -21.11* | -3.25* | - | - | - |
Free Cahsflow | -8.3% | -48,548 | -44,810 | -39,617 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -38.7% | 52.00 | 85.00 | 99.00 | 115 | 126 |
Current Assets | -39.8% | 38.00 | 64.00 | 45.00 | 60.00 | 67.00 |
Cash Equivalents | -62.6% | 4.00 | 10.00 | 23.00 | 34.00 | 45.00 |
Inventory | 18.8% | 4.00 | 3.00 | 2.00 | - | - |
Net PPE | 22.5% | 4.00 | 3.00 | 1.00 | 35.00 | 33.00 |
Liabilities | -8.9% | 33.00 | 36.00 | 36.00 | 36.00 | 36.00 |
Current Liabilities | -13.7% | 28.00 | 32.00 | 30.00 | 8.00 | 8.00 |
Shareholder's Equity | -61.1% | 19.00 | 48.00 | 63.00 | 79.00 | 91.00 |
Retained Earnings | -13.9% | -275 | -242 | -223 | -206 | -194 |
Additional Paid-In Capital | 1.4% | 295 | 291 | 288 | 286 | 285 |
Shares Outstanding | 37.3% | 12.00 | 9.00 | 9.00 | 9.00 | 9.00 |
Minority Interest | NaN% | - | - | - | - | - |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 7.2% | -39,041 | -42,092 | -37,480 | -33,203 | -34,608 |
Share Based Compensation | 0.5% | 4,802 | 4,778 | 4,377 | 3,794 | 2,894 |
Cashflow From Investing | -554.9% | -232 | 51.00 | -5,127 | -8,512 | -13,043 |
Cashflow From Financing | 60.7% | -1,923 | -4,896 | -6,125 | -3,203 | 1,545 |
100%
100%
93.8%
Y-axis is the maximum loss one would have experienced if Ibio was unfortunately bought at previous high price.
-35.8%
-47.0%
-51.0%
-64.2%
FIve years rolling returns for Ibio.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-02-24 | SRS Capital Advisors, Inc. | new | - | 16.00 | 16.00 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -33,000 | - | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | new | - | 356 | 356 | -% |
2023-02-15 | Steward Partners Investment Advisory, LLC | new | - | 28.00 | 28.00 | -% |
2023-02-15 | Virtu Financial LLC | new | - | 21,000 | 21,000 | -% |
2023-02-15 | UNITED CAPITAL FINANCIAL ADVISERS, LLC | sold off | -100 | -2,000 | - | -% |
2023-02-15 | JANE STREET GROUP, LLC | sold off | -100 | -5,000 | - | -% |
2023-02-15 | Steward Partners Investment Advisory, LLC | sold off | -100 | - | - | -% |
2023-02-14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 59,926 | 59,926 | -% |
2023-02-14 | Bank of New York Mellon Corp | sold off | -100 | -22,000 | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 5.28% | 475,593 | SC 13G | |
Jul 08, 2022 | blackrock inc. | 1.8% | 3,960,718 | SC 13G | |
Feb 03, 2022 | blackrock inc. | 7.1% | 15,476,683 | SC 13G/A | |
Feb 02, 2021 | blackrock inc. | 5.5% | 11,575,051 | SC 13G | |
Aug 13, 2020 | eastern capital ltd | 0.6% | 1e+06 | SC 13D/A | |
Aug 11, 2020 | eastern capital ltd | 5.8% | 8,629,693 | SC 13D/A | |
Aug 07, 2020 | eastern capital ltd | 22.3% | 33,114,597 | SC 13D/A | |
Aug 06, 2020 | eastern capital ltd | 22.3% | 33,114,597 | SC 13D/A | |
Mar 31, 2020 | eastern capital ltd | 28.7% | 37,382,734 | SC 13D/A | |
Mar 05, 2020 | eastern capital ltd | 35.6% | 37,382,734 | SC 13D/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 0.31 -84.73% | 0.32 -84.24% | 0.38 -81.28% | 0.47 -76.85% | 0.59 -70.94% |
Current Inflation | 0.30 -85.22% | 0.32 -84.24% | 0.37 -81.77% | 0.45 -77.83% | 0.55 -72.91% |
Very High Inflation | 0.30 -85.22% | 0.32 -84.24% | 0.36 -82.27% | 0.42 -79.31% | 0.51 -74.88% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 13, 2023 | 8-K | Current Report | |
Feb 23, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 424B3 | Prospectus Filed | |
Feb 21, 2023 | 8-K | Current Report | |
Feb 16, 2023 | 8-K | Current Report | |
Feb 14, 2023 | 10-Q | Quarterly Report | |
Feb 14, 2023 | 3 | Insider Trading | |
Feb 09, 2023 | SC 13G | Major Ownership Report | |
Jan 25, 2023 | 8-K | Current Report | |
Jan 24, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-02-21 | Brenner Martin | sold | -7,037 | 1.77 | -3,976 | see remarks |
2023-01-20 | Brenner Martin | acquired | - | - | 130,000 | interim ceo and cso |
2022-11-11 | Lutz Robert Matthew | acquired | - | - | 100,057 | see remarks |
2022-11-11 | Brenner Martin | acquired | - | - | 95,348 | chief scientific officer |
2022-03-10 | Lutz Robert Matthew | sold | -8,510 | 0.3456 | -24,625 | see remarks |
2021-03-04 | Lutz Robert Matthew | acquired | - | - | 232,000 | see remarks |
2020-12-01 | Maddux Randy Joe | acquired | - | - | 309,000 | chief operating officer |
2020-08-11 | Eastern Capital LTD | sold | -46,330,400 | 2.9204 | -15,864,400 | - |
2020-08-10 | Eastern Capital LTD | sold | -28,429,600 | 3.9133 | -7,264,860 | - |
2020-08-07 | Eastern Capital LTD | sold | -5,185,580 | 3.8253 | -1,355,600 | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |
Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||
Revenues | $ 0 | $ 0 | $ 84 | |
Operating expenses: | ||||
Research and development | 2,779 | 1,859 | $ 5,327 | 2,993 |
General and administrative | 7,794 | 5,372 | 12,882 | 9,547 |
Total operating expenses | 10,573 | 7,231 | 18,209 | 12,540 |
Operating loss | (10,573) | (7,231) | (18,209) | (12,456) |
Other income (expense): | ||||
Interest expense | (31) | 0 | (31) | |
Interest income | 41 | 35 | 140 | 71 |
Royalty income | 0 | 5 | 5 | |
Total other income (expense) | 10 | 40 | 109 | 76 |
Consolidated net loss from continuing operations | (10,563) | (7,191) | (18,100) | (12,380) |
Net loss attributable to noncontrolling interest | 0 | 0 | 1 | |
Net loss attributable to iBio, Inc. from continuing operations | (10,563) | (7,191) | (18,100) | (12,379) |
Preferred stock dividends - iBio CDMO Tracking Stock | 0 | (22) | 0 | (88) |
Net loss available to iBio, Inc. stockholders from continuing operations | (10,563) | (7,213) | (18,100) | (12,467) |
Loss from discontinued operations | (22,990) | (4,729) | (33,583) | (8,480) |
Net loss available to iBio, Inc. stockholders | (33,553) | (11,942) | (51,683) | (20,947) |
Comprehensive loss: | ||||
Consolidated net loss | (33,553) | (11,920) | (51,683) | (20,860) |
Other comprehensive loss - unrealized gain ( loss) on debt securities | 56 | (27) | 46 | (28) |
Comprehensive loss | $ (33,497) | $ (11,947) | $ (51,637) | $ (20,888) |
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations | $ (1.08) | $ (0.83) | $ (1.94) | $ (1.43) |
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations | (1.08) | (0.83) | (1.94) | (1.43) |
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations | (2.34) | (0.54) | (3.60) | (0.97) |
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations | (2.34) | (0.54) | (3.60) | (0.97) |
Loss per common share attributable to iBio, Inc. stockholders - basic - total | (3.42) | (1.37) | (5.54) | (2.40) |
Loss per common share attributable to iBio, Inc. stockholders - diluted - total | $ (3.42) | $ (1.37) | $ (5.54) | $ (2.40) |
Weighted-average common shares outstanding - basic | 9,807 | 8,715 | 9,324 | 8,715 |
Weighted-average common shares outstanding - diluted | 9,807 | 8,715 | 9,324 | 8,715 |
Condensed Consolidated Balance Sheets - USD ($) | Dec. 31, 2022 | Jun. 30, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,696,000 | $ 22,676,000 |
Investments in debt securities | 5,929,000 | 10,845,000 |
Accounts receivable - trade | 970,000 | 1,000,000 |
Settlement receivable - current portion | 5,100,000 | 5,100,000 |
Convertible promissory note receivable and accrued interest | 1,669,000 | |
Prepaid expenses and other current assets | 414,000 | 1,549,000 |
Current assets held for sale | 20,457,000 | 3,900,000 |
Total Current Assets | 38,235,000 | 45,070,000 |
Restricted cash | 253,000 | 5,996,000 |
Convertible promissory note receivable and accrued interest | 1,631,000 | |
Finance lease right-of-use assets, net of accumulated amortization | 746,000 | |
Operating lease right-of-use asset | 2,873,000 | 3,068,000 |
Fixed assets, net of accumulated depreciation | 4,245,000 | 1,373,000 |
Intangible assets, net of accumulated amortization | 5,398,000 | 4,851,000 |
Security deposits | 50,000 | 29,000 |
Prepaid expenses - noncurrent | 74,000 | |
Noncurrent assets held for sale | 37,314,000 | |
Total Assets | 51,800,000 | 99,406,000 |
Current liabilities: | ||
Accounts payable | 4,002,000 | 4,264,000 |
Accrued expenses | 5,001,000 | 3,764,000 |
Finance lease obligations - current portion | 259,000 | |
Operating lease obligation - current portion | 315,000 | 91,000 |
Equipment financing payable - current portion | 152,000 | |
Term note payable - net of deferred financing costs | 16,011,000 | 22,161,000 |
Contract liabilities | 88,000 | 100,000 |
Current liabilities related to assets held for sale | 1,947,000 | 56,000 |
Total Current Liabilities | 27,775,000 | 30,436,000 |
Finance lease obligations - net of current portion | 490,000 | |
Operating lease obligation - net of current portion | 3,324,000 | 3,514,000 |
Equipment financing payable - net of current portion | 323,000 | |
Accrued expenses - noncurrent | 1,065,000 | |
Noncurrent liabilities related to assets held for sale | 1,971,000 | |
Total Liabilities | 32,977,000 | 35,921,000 |
iBio, Inc. Stockholders' Equity: | ||
Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively | ||
Common stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2022 and June 30, 2022; 12,368,287 and 8,727,158 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively | 12,000 | 9,000 |
Additional paid-in capital | 294,591,000 | 287,619,000 |
Accumulated other comprehensive loss | (167,000) | (213,000) |
Accumulated deficit | (275,613,000) | (223,930,000) |
Total iBio, Inc. Stockholders' Equity | 18,823,000 | 63,485,000 |
Total Liabilities and Equity | $ 51,800,000 | $ 99,406,000 |